4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Rein Therapeutics Inc. (RNTX) operates in the Biotechnology industry and is headquartered in Austin, United States with about 10 employees. Its market capitalization is roughly $85 million. In the fiscal year ended 2025-12-31, RNTX reported $0M in revenue and ($50M) in net income.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($22M) | ($28M) | ($15M) | ($28M) | — |
| Net Income | ($50M) | ($63M) | ($16M) | ($27M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($5M) | ($4M) | ($6M) | ($7M) | ($6M) | — |
| Net Income | ($6M) | ($32M) | ($6M) | ($7M) | ($6M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $24M | $62M | $106M | $22M | — |
| Total Liabilities | $52M | $53M | $99M | $3M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RNTX viewer.
About TickerBase · Data methodology & sources